Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc.
2020 · Licensing/Option · $475M · Complete
Announcement Sentiment
60
Positive
Outcome Score
55
Mixed — partial payoff, real shortfalls.
BMS licensed Dragonfly's IL-12 program (DF6002/BMS-986415) for $475M upfront and expanded its TriNKET NK-cell-engager collaboration. In Feb 2023, BMS returned all rights to the IL-12 asset DF6002 (then in Phase 1) to Dragonfly, ending the headline component of this deal; the upfront was retained by Dragonfly. The broader BMS-Dragonfly TriNKET relationship continued, with BMS holding six licensed TriNKET candidates (two in clinic) and a separate Jan 2023 neuroinflammation TriNKET license.
Key facts
AnnouncedMar 02, 2020
ClosedAug 17, 2020
Deal value$475M
Deal typeLicensing/Option
Therapeutic areaOncology
IndicationsSolid tumors, Hematologic malignancies
Key assetsDF6002 (BMS-986415), TriNKET candidates
MechanismIL-12 immunotherapy, NK cell engager (TriNKET)